PLX Pharma (PLXP) recently announced that VAZALORE is now on shelves at major retailers and e-commerce sites nationwide, notes biotech sector expert John McCamant, editor of The Medical Technology Stock Letter.

A national television campaign has also kicked-off and features spots on high-visibility sports programming (golf so far) as well as popular cable networks.

In our view, PLX Pharma’s management team has executed very well since our recent initial recommendation by signing a string of partnerships with huge OTC retailers. 

The team is continuing to execute with the recent timely launch of VAZALORE, the first and only FDA approved liquid-filled aspirin.

We are excited that VAZALORE has hit the shelves nationally and look forward to communicating the benefits of this innovative aspirin therapy to millions of patients at risk for vascular disease,” stated Natasha Giordano, Chief Executive Officer of PLx.

“We are confident consumers will recognize VAZALORE as a breakthrough in aspirin delivery, designed to help protect the stomach while providing all of the benefits of aspirin to help prevent another heart attack or clot-related stroke.”

With the launch underway, the company will be able to report some revenue from VAZALORE stocking on their Q3 financials. As revenue is booked as soon as each individual retailer receives product, so we could see an upside surprise in the upcoming earnings release.

We expect the Q4 revenue to be even stronger as the company will have implemented a broad OTC advertising campaign and will also be able to market to key opinion leading cardiologists at upcoming medical meetings including AHA and ACC. The stock is a buy under $22 for a target price of $35.

Subscribe to The Medical Technology Stock Letter here…